Cartilage regeneration refers to the development and application of medical techniques and therapies to restore damaged or degenerated cartilage tissue in the human body. Cartilage is a connective tissue that plays a crucial role in supporting and cushioning joints, and its damage can result from injuries, arthritis, or other degenerative conditions. The market encompasses a range of products, treatments, and technologies designed to promote the repair and regeneration of cartilage. Some key approaches in this field include cell-based therapies, tissue engineering, orthopedic implants, regenerative medicine products, arthroscopic procedures, and cartilage repair devices.
The cartilage regeneration market has grown significantly due to the rising prevalence of joint-related disorders, sports injuries, and an aging population. Advances in biotechnology, tissue engineering, and regenerative medicine have contributed to developing innovative solutions in this field.
Access full Report @ https://www.databridgemarketresearch.com/reports/us-and-europe-cartilage-regeneration-market
Data Bridge Market Research analyzes that the U.S. and Europe Cartilage Regeneration Market is expected to reach USD 1,474,396.99 thousand by 2031 from USD 590,964.54 thousand in 2023, growing at a CAGR of 12.8% in the forecast period of 2024 to 2031.
Key Findings of the Study
Rising Prevalence of Osteoarthritis
Osteoarthritis is more prevalent among older individuals, and with the increase in the aging population, there is a higher incidence of this condition. As a result of aging, the joints become more susceptible to osteoarthritis. The elderly population, therefore, represents a substantial market for cartilage regeneration therapies. Obesity is a well-established risk factor for osteoarthritis, particularly in weight-bearing joints such as the knees and hips. The worldwide increase in obesity rates has contributed to a higher incidence of osteoarthritis, especially in younger age groups. Individuals with obesity often experience greater stress on their joints, accelerating cartilage degeneration and creating a demand for regenerative solutions.
The rising prevalence of osteoarthritis is a compelling factor driving the growth of the cartilage regeneration market. The demand for advanced and regenerative solutions to address cartilage damage is expected to continue growing as the global population ages and risk factors for osteoarthritis persist. The market is likely to see further advancements, research, and innovations to meet the rising healthcare needs associated with osteoarthritis, which is driving the market growth.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Thousand
|
|
Segments Covered
|
Type (Hyaline Cartilage, Fibro Cartilage, and Elastic Cartilage), Treatment Modality (Cell-Based and Non-cell Based), Treatment Type (Intrinsic Repair Stimulus and Palliative), Application Site (Knee, Hip, Ankle, Spine, and Others), Surgical Procedure (Osteochondral Transplantation, Autologous Chondrocyte Implantation, Matrix Autologous Cartilage Implantation (MACI), Chondroplasty and Microfracture, Osteotomy, Arthroscopy, Abrasion Arthroplasty, Juvenile Allograft Fragments, and Others), End User (Hospitals and Clinics, Academic and Research Institutes, Ambulatory Surgical Centers, Orthocenters, and Others)
|
|
Countries Covered
|
U.S., Germany, U.K, France, Italy, Spain, Russia, Poland, Switzerland, Netherlands, Turkey, Sweden, Belgium, Denmark, Finland, Norway, and Rest of Europe
|
|
Market Players Covered
|
Zimmer Biomet (U.S.), Vericel Corporation (U.S.), and Arthrex, Inc (U.S), CONMED Corporation (U.S.), RTI Surgical (U.S), Smith+Nephew. (U.K), Anika Therapeutics, Inc. (U.S), Geistlich Pharma AG (Switzerland), AlloSource (U.S.), Bioinova, A.S (U.S), TETEC AG (Germany), meidrix biomedicals GmbH (Germany), Lamina Therapeutics (France), CO.DON (Germany), Novartis AG (Switzerland), Cartilage Inc. (U.S.), and Histogen Inc. (U.S), among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis
The U.S. and Europe cartilage regeneration market is categorized into six notable segments based on type, treatment modality, treatment type, application site, surgical procedure, and end user.
- On the basis of type, the U.S. and Europe cartilage regeneration market is segmented into hyaline cartilage, fibro cartilage, and elastic cartilage
In 2024, the hyaline cartilage segment is expected to dominate the U.S. and Europe cartilage regeneration market
In 2024, the hyaline cartilage segment is expected to dominate the market with 65.86% market share due to the rising prevalence of joint injuries and osteoarthritis.
- On the basis of treatment modality, the U.S. and Europe cartilage regeneration market is segmented into cell-based and non-cell based
In 2024, the cell-based segment is expected to dominate the U.S. and Europe cartilage regeneration market
In 2024, the cell-based segment is expected to dominate the market with an 85.18% market share due to rising demand for minimally invasive procedures.
- On the basis of treatment type, the U.S. and Europe cartilage regeneration market is segmented into intrinsic repair stimulus and palliative. In 2024, intrinsic repair stimulus segment is expected to dominate the market with a market share of 82.73%
- On the basis of application site, the U.S. and Europe cartilage regeneration market is segmented into knee, hip, ankle, spine and others. In 2024, knee segment is expected to dominate the market with a market share of 69.61%
- On the basis of surgical procedure, the U.S. and Europe cartilage regeneration market is segmented into Osteochondral Transplantation, Autologous chondrocyte implantation, Matrix Autologous Cartilage Implantation (MACI), chondroplasty and microfracture, osteotomy, arthroscopy, abrasion arthroplasty, juvenile allograft fragments, and others. In 2024, osteochondral transplantation segment is expected to dominate the market with a market share of 31.10%
- On the basis of end user, the U.S. and Europe cartilage regeneration market is segmented into hospitals and clinics, academic and research institutes, ambulatory surgical centers, orthocenters, and others. In 2024, hospitals and clinics segment is expected to dominate the market with a market share of 61.58%
Major Players
Data Bridge Market Research analyzes Zimmer Biomet (U.S), Vericel Corporation (U.S), Arthrex, Inc. (U.S), CONMED Corporation (U.S), and RTI Surgical (U.S) as the major market players of the U.S. and Europe cartilage regeneration market.
Market Developments
- In May 2023, Cartilage Inc., a biomedical startup from the University of California Irvine, is developing a product that will restore TMJ function by regenerating missing tissue and repairing defects in the jaw joint. This has helped the company to strengthen its product portfolio
- In September 2021, Novartis AG announced that the U.S Food and Drug Administration (FDA) had granted fast track designation for LNA043 for treating osteoarthritis of the knee. This has helped the company establish its presence in osteoarthritis products
- In September 2020, Lamina Therapeutics announced that it relies on the research work of the Strasbourg scientific team coordinated by Prof. Nadia JESSEL, Director of the INSERM UMR 1260 / RNM (Regenerative NanoMedicine) unit and founding member of LAMINA THERAPEUTICS. This innovative technology aims to develop a new generation of combined Advanced Therapy Medicinal Product (cATMP) for regenerative medicine, particularly for reconstructing bone, cartilage, and the osteochondrial unit
- In January 2021, Vericel Corporation a leader in advanced therapies for the sports medicine and severe burn care markets, announced that United Healthcare has expanded its medical policy for MACI (autologous cultured chondrocytes on porcine collagen membrane) to include coverage for patients with symptomatic full-thickness cartilage defects in the patella and multiple cartilage defects in the knee
- In October 2020, Cartilage Inc. received a Phase I USD 252,000 Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). The startup has used this grant to investigate the feasibility of their product Hyaleon, a scaffold-free, tissue-engineered cartilage implant capable of healing
Regional Analysis
Geographically, the countries covered in the market report are U.S., Germany, U.K, France, Italy, Spain, Russia, Poland, Switzerland, Netherlands, Turkey, Sweden, Belgium, Denmark, Finland, Norway, and Rest of Europe.
As per Data Bridge Market Research analysis:
The U.S. is expected to be the dominant and fastest-growing country in the U.S. and Europe cartilage regeneration market
The U.S. is expected to dominate the market due to the rising prevalence of joint injuries and osteoarthritis, and a favorable regulatory environment fostering innovation also it is expected to grow due to the rising prevalence of osteoarthritis and rising healthcare expenditure, to rising demand for minimally invasive procedures.
For more detailed information about U.S. and Europe cartilage regeneration market Report, click here – https://www.databridgemarketresearch.com/reports/us-and-europe-cartilage-regeneration-market
